公开(公告)号：WO2018093866A1

公开(公告)日：2018-05-24

申请号：PCT/US2017061757

申请日：2017-11-15

Applicant: REGENERON PHARMA

Inventor： BABB ROBERT ,  CHEN GANG ,  DALY CHRISTOPHER ,  DASILVA JOHN ,  MACDONALD DOUGLAS

IPC: C07K16/28 ,  A61K47/68

CPC classification number: C07K16/2863 ,  A61K31/537 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6857 ,  A61K47/6863 ,  A61P35/00 ,  C07K16/3023 ,  C07K16/3046 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

公开(公告)号：WO2014004427A2

公开(公告)日：2014-01-03

申请号：PCT/US2013047476

申请日：2013-06-25

Applicant: REGENERON PHARMA

Inventor： DALY CHRISTOPHER ,  THURSTON GAVIN ,  PADADOPOULOS NICHOLAS J

IPC: C07K16/28

CPC classification number: A61K39/39558 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.

Abstract translation: 本发明提供了与EGFR结合的抗体及其使用方法。 根据本发明的某些实施方案，抗体是以高亲和力结合人EGFR的完全人抗体。 在某些实施方案中，本发明的抗体能够抑制表达高水平EGFR和/或诱导这些细胞的抗体依赖性细胞介导的细胞毒性（ADCC）的肿瘤细胞的生长。 本发明的抗体可用于治疗各种癌症以及其他EGFR相关病症。

公开(公告)号：WO2014004427A8

公开(公告)日：2014-12-18

申请号：PCT/US2013047476

申请日：2013-06-25

Applicant: REGENERON PHARMA

Inventor： DALY CHRISTOPHER ,  THURSTON GAVIN ,  PAPADOPOULOS NICHOLAS J

IPC: C07K16/28

CPC classification number: A61K39/39558 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.

公开(公告)号：WO2013048883A3

公开(公告)日：2013-06-27

申请号：PCT/US2012056446

申请日：2012-09-21

Applicant: REGENERON PHARMA

Inventor： DALY CHRISTOPHER ,  MACDONALD DOUGLAS ,  DUAN XUNBAO

IPC: C07K16/32 ,  A61K39/395

CPC classification number: A61K39/39558 ,  A61K31/517 ,  A61K31/5377 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.

Abstract translation: 本发明提供了结合ErbB3的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人ErbB3结合的完全人抗体。 在某些实施方案中，本发明的抗体阻断ErbB3与ErbB3配体如神经调节蛋白1的相互作用。本发明的抗体可用于治疗各种癌症。